Q3 2025 Management View Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X ...

A quiet revolution is reshaping enterprise data engineering. Python developers are building production data pipelines in ...

Discover V2X’s record Q3 2025 earnings, higher financial guidance, and growth outlook—despite government shutdown delays.

Discover key insights from Nuvation Bio's Q3 2025 earnings: rapid IBTROZI uptake, strong financials, and growth strategies in oncology.

Q3 2025 Management View Juan Luciano, Chairman, CEO & President, reported "adjusted earnings per share of $0.92 and total segment operating profit of $845 million for the third quarter." He outlined a ...

The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.

“While powerful proprietary Large Language Models (LLMs) were an option, they often fell short in understanding [South East ...

In October 2025, Foreign Portfolio Investors (FPIs) invested ₹14,610 crore in Indian stocks, ending a three-month selling ...

Veralto’s third quarter results reflected steady execution across its core Water Quality and Product Quality and Innovation ...

Bloom Energy’s third quarter results were marked by a notable acceleration in demand for its on-site power solutions, ...

A tech build-out reshapes Umatilla and its neighbours with jobs, money and megaprojects—along with rising costs and new risks ...

Xenon Pharmaceuticals Inc (XENE) exceeds patient enrollment goals in its Phase 3 XTOL2 study and maintains a robust cash ...